$KTTA News

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2

HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Pasithea Therapeutics Amends Clinical Study Protocol For Phase 1/1b Trial Of PAS-004 In Neurofibromatosis Type 1 Patients With Symptomatic Inoperable, Incompletely Resected, Or Recurrent Plexiform Neurofibroma

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophic Lateral Sclerosis

Pasithea Therapeutics Corp. Receives FDA Orphan Drug Designation For MEK1/2 Inhibitor For Treatment Of Amyotrophic Lateral Sclerosis

Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?

HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Pasithea Therapeutics Wins FDA Rare Pediatric Disease Tag For NF1 Drug Affecting ~115,000 Americans

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Pasithea Therapeutics Says FDA Grants Fast Track Designation To PAS-004 For Treatment Of NF1-Associated PN Causing Significant Morbidity

Pasithea Therapeutics Says FDA Grants Fast Track Designation To PAS-004 For Treatment Of NF1-Associated PN Causing Significant Morbidity